Piper Sandler Reiterates Overweight Rating on Elevation Oncology (ELEV)

June 28, 2024 8:20 AM EDT Send to a Friend
Piper Sandler analyst Biren Amin reiterated an Overweight rating and $10.00 price target on Elevation Oncology (NASDAQ: ELEV).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login